[Show abstract][Hide abstract] ABSTRACT: The purpose of this study was to develop and test an innovative yoga-based behavioral intervention for smoking cessation based on social cognitive theory and compare it with an existing self-help based program. In both the groups, the antecedents of quitting based on social cognitive theory, namely, self-efficacy for quitting and self-control for quitting were tracked for six months along with self-reported daily consumption of cigarettes, self-efficacy for yoga, and past week performance of yoga behaviors. A valid and reliable 23-item instrument was utilized. The study employed an experimental design. Twenty one participants recruited in this study after informed consent and randomly assigned to the two groups. Seven (33.3%) participants completed the study protocol and one participant who was in the yoga group was successful in quitting smoking. Statistically significant improvements occurred in the social cognitive-theory based yoga group over the self-help group for self-control for quitting (p<0.001) and performance of yoga behaviors (p<0.05). This pilot study suggested that a social cognitive theory based yoga intervention was more efficacious in influencing the antecedents of smoking cessation than a self-help approach. This study lends support for developing and testing future interventions regarding the use of yoga as a behavioral method for smoking cessation.
[Show abstract][Hide abstract] ABSTRACT: Autism was recently associated with a urinary porphyrin pattern indicative of mercury toxicity in a large cohort of French children. The IRB of the Institute for Chronic Illnesses approved the present study. A total of 37 consecutive American patients (> or = 7 years-old) with autism spectrum disorders (ASDs) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-DSM IV), born from 1983-1998, that presented to the Genetic Centers of America for outpatient genetic evaluations were prospectively examined for urinary prophryin levels (LabCorp, Inc.) from June 2005-June 2006. Imaging and laboratory testing were conducted on each patient to rule-out other causal factors for their ASDs. As controls, age-, sex-, and race-matched neurotypical ASD siblings were examined. An apparent dose-response effect was observed between autism severity and increased urinary coproporphyrins. Patients with non-chelated autism (2.25-fold, 83% had levels > 2 SD above the control mean) and non-chelated ASDs (2-fold, 58% had levels > 2 SD above the control mean), but not patients with non-chelated pervasive developmental delay-not otherwise specified (PDD-NOS) or Asperger's disorder (1.4-fold, 46% had levels > 2 SD above the control mean), had significantly increased median coproporphyrin levels versus controls. A significant increase (1.7-fold) in median coproporphyrin levels was observed among non-chelated ASD patients versus chelated ASD patients. Porphyrins should be routinely clinically measured in ASDs, and potential ASD treatments should consider monitoring porphyrin levels. Additional research should be conducted to evaluate the potential role for mercury exposure in some ASDs.
Neurotoxicity Research 09/2006; 10(1):57-64. DOI:10.1007/BF03033334 · 3.54 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: Exercise is routinely recommended as an aid to smoking cessation by specialist clinics and self-help materials. Fifteen trials have compared an exercise programme plus a smoking cessation programme, or an exercise programme alone, to a cessation programme alone or a cessation programme plus a health education programme, among smokers who were motivated to quit. Since these studies used different types of exercise programmes, and varied in the duration of follow up, the results were not combined. In one study with a difference in quit rates of borderline significance, the exercise component more than doubled the likelihood of not smoking after 12 months.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.